ECSP045367A - "derivados de bencimidazol utiles como antagonistas de histamina h3" - Google Patents

"derivados de bencimidazol utiles como antagonistas de histamina h3"

Info

Publication number
ECSP045367A
ECSP045367A EC2004005367A ECSP045367A ECSP045367A EC SP045367 A ECSP045367 A EC SP045367A EC 2004005367 A EC2004005367 A EC 2004005367A EC SP045367 A ECSP045367 A EC SP045367A EC SP045367 A ECSP045367 A EC SP045367A
Authority
EC
Ecuador
Prior art keywords
formula
compounds
useful
histamine antagonists
allergy
Prior art date
Application number
EC2004005367A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045367A publication Critical patent/ECSP045367A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen nuevos compuestos de la formulan la cual R1 es benzimidazolilo opcionalmente sustituido ó un derivado del mismo; R2 es arilo ó heteroarilo opcionalmente sustituido; M1 y M2 son C(R3) ó N; Q es -N(R8)-, -S- u -O-; y las variables remanentes son tal como se definen en la memoria. Asimismo se describen composiciones farmacéuticas que comprenden los compuestos de la fórmula 1 y los métodos para el tratamiento de varias enfermedades ó trastornos tales como alergia, afecciones de las vías respiratorias inducidas por la alergia, y congestión (por ejemplo congestión nasal), usando los compuestos de la fórmula I. Asimismo se describen métodos para el tratamiento de dichas enfermedades ó trastornos usando los compuestos de la fórmula I en combinación con un antagonista del receptor H1.
EC2004005367A 2002-04-18 2004-10-15 "derivados de bencimidazol utiles como antagonistas de histamina h3" ECSP045367A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37373102P 2002-04-18 2002-04-18

Publications (1)

Publication Number Publication Date
ECSP045367A true ECSP045367A (es) 2004-11-26

Family

ID=29251069

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005367A ECSP045367A (es) 2002-04-18 2004-10-15 "derivados de bencimidazol utiles como antagonistas de histamina h3"

Country Status (26)

Country Link
EP (1) EP1499316B1 (es)
JP (1) JP4384918B2 (es)
KR (1) KR100827470B1 (es)
CN (1) CN100522166C (es)
AR (1) AR040405A1 (es)
AT (1) ATE389406T1 (es)
AU (1) AU2003223627B2 (es)
BR (1) BR0309348A (es)
CA (1) CA2481940A1 (es)
CY (1) CY1110363T1 (es)
DE (1) DE60319813T2 (es)
DK (1) DK1499316T3 (es)
EC (1) ECSP045367A (es)
ES (1) ES2301791T3 (es)
IL (1) IL164584A (es)
MX (1) MXPA04010173A (es)
NO (1) NO20045002L (es)
NZ (1) NZ535763A (es)
PE (1) PE20040684A1 (es)
PL (1) PL373889A1 (es)
PT (1) PT1499316E (es)
RU (1) RU2323935C2 (es)
SI (1) SI1499316T1 (es)
TW (1) TW200306183A (es)
WO (1) WO2003088967A1 (es)
ZA (1) ZA200407984B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399866B2 (en) 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
HRP20080541T3 (en) 2003-04-23 2008-12-31 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
JPWO2006038738A1 (ja) * 2004-10-08 2008-05-15 武田薬品工業株式会社 受容体機能調節剤
EP1848696A1 (en) 2005-01-21 2007-10-31 Schering Corporation Imidazole and benzimidazole derivates useful as histamine h3 antagonists
DE602006010870D1 (de) * 2005-06-20 2010-01-14 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
CA2609957A1 (en) * 2005-06-20 2007-01-04 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
WO2007035703A1 (en) * 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
JP4870163B2 (ja) * 2005-09-30 2012-02-08 エフ.ホフマン−ラ ロシュ アーゲー Mch受容体アンタゴニストとしてのインダン誘導体
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007078839A2 (en) 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
JP2009521448A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンh3アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
CA2634235A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
BRPI0707916A2 (pt) * 2006-01-13 2011-05-17 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e uso destes compostos
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
CN101809021B (zh) * 2007-09-11 2013-04-24 雅培制药有限公司 八氢-吡咯并[3,4-b]吡咯n-氧化物
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
CA2785536C (en) 2009-12-30 2018-02-27 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
WO2012177852A1 (en) 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
DK2723741T3 (en) 2011-06-24 2016-06-06 Arqule Inc SUBSTITUTED imidazopyridinyl-aminopyridine compounds
KR101127756B1 (ko) 2011-09-02 2012-03-23 한국과학기술원 Git1 유전자 결손 마우스 및 이를 이용한 약물 스크리닝 방법
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP6046646B2 (ja) 2014-01-10 2016-12-21 信越化学工業株式会社 オニウム塩、化学増幅型ポジ型レジスト組成物、及びパターン形成方法
US10595550B2 (en) * 2014-01-22 2020-03-24 Vision Pharma, Llc Therapeutic composition including carbonated solution
WO2017035114A1 (en) * 2015-08-25 2017-03-02 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as cb-1 inverse agonists
JP2022522534A (ja) 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Prmt5を標的にする化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD290192A5 (de) * 1986-11-13 1991-05-23 Eisai Co. Ltd,Jp Pyridinderivat mit antiulzeroeser wirkung
ES2048109B1 (es) * 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
CA2124306C (en) * 1993-05-26 2004-04-06 Masami Muraoka Quinazolinone derivatives
US6211199B1 (en) * 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
IL125578A (en) * 1996-02-21 2002-09-12 Aventis Pharma Inc N-Methyl - N - 4 - (4 (H1 - Benzimidazole-2 - Eyal - Amino) Pipridine - 1 - Eyal) 2 - (Aryl) Butyl benzamides and pharmaceutical preparations useful for the treatment of allergic diseases
NZ337749A (en) * 1997-05-01 2000-09-29 Nissan Chemical Ind Ltd Benzimidazole derivative and their use in allergy-related disease
US6133291A (en) * 1998-10-16 2000-10-17 Schering Corporation N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
MXPA03002448A (es) * 2000-09-20 2003-06-19 Schering Corp Eimidazoles sustituidos como agonistas o antagonistas duales h1 y h3 de histamina.
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
CN100360130C (zh) * 2002-04-18 2008-01-09 先灵公司 用作组胺h3拮抗剂的1-(4-哌啶基)苯并咪唑酮

Also Published As

Publication number Publication date
DK1499316T3 (da) 2008-07-21
MXPA04010173A (es) 2005-02-03
ATE389406T1 (de) 2008-04-15
AU2003223627C1 (en) 2003-11-03
AU2003223627A1 (en) 2003-11-03
HK1067981A1 (en) 2005-04-22
DE60319813T2 (de) 2009-04-23
NZ535763A (en) 2007-06-29
RU2323935C2 (ru) 2008-05-10
PL373889A1 (en) 2005-09-19
ZA200407984B (en) 2005-10-18
AU2003223627B2 (en) 2006-10-12
PE20040684A1 (es) 2004-10-05
EP1499316A1 (en) 2005-01-26
EP1499316B1 (en) 2008-03-19
IL164584A (en) 2010-12-30
CN100522166C (zh) 2009-08-05
NO20045002L (no) 2005-01-18
SI1499316T1 (sl) 2008-08-31
WO2003088967A1 (en) 2003-10-30
PT1499316E (pt) 2008-06-30
KR20040099445A (ko) 2004-11-26
BR0309348A (pt) 2005-03-01
RU2004133764A (ru) 2005-07-20
IL164584A0 (en) 2005-12-18
JP4384918B2 (ja) 2009-12-16
TW200306183A (en) 2003-11-16
JP2005529116A (ja) 2005-09-29
CY1110363T1 (el) 2012-05-23
DE60319813D1 (de) 2008-04-30
CA2481940A1 (en) 2003-10-30
KR100827470B1 (ko) 2008-05-06
AR040405A1 (es) 2005-04-06
ES2301791T3 (es) 2008-07-01
CN1658874A (zh) 2005-08-24

Similar Documents

Publication Publication Date Title
MY132566A (en) Benzimidazolone histamine h3 antagonists
CY1110363T1 (el) Παραγωγα (1-4-πιπεριδινυλ)βενζιμιδαζολιου χρησιμα σαν ανταγωνιστες η3 ισταμινης
PT1513826E (pt) Novos derivados de indolilpiperidina como agentes anti-histaminicos e antialergicos potentes
NO20050164L (no) Nye quinuklidin-amid-derivater
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
UY28692A1 (es) Nuevos derivados de quinolina
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
DE602006017694D1 (de) C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
PL376440A1 (en) Pyridopyrrolizine and pyridoindolizine derivatives
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
NO20070336L (no) Indolderivater som histamin-reseptorantagonister
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
AR056511A1 (es) Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
ATE418548T1 (de) Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten
ATE455756T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
AR050208A1 (es) Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
EA200600694A1 (ru) Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение
NO20080033L (no) Kinolinderivater som NK3-antagonister
UY28906A1 (es) Derivados de pirimidina que son antagonistas del receptor vitronectina
WO2008077810A3 (en) Spiro-piperidine derivatives
CY1112218T1 (el) Νεα παραγωγα ανταγωνιστες υποδοχεα βιτρονεκτινης, μεθοδος παρασκευης τους, η εφαρμογη τους ως φαρμακα και φαρμακευτικες συνθεσεις που τα περιεχουν